There
is considerable excitement around the potential of AndroScience's ASC-J9 in the
acne market. ASC-J9 not only represents a novel mechanism of action, but also
its entry to the market will be a much-needed addition to a stagnant market.
ASC-J9 functions to target the principal hormone receptor associated with acne,
the androgen receptor, a cause of acne in both men and women.
In
addition to use in female patients with moderate to severe acne, ASC-J9 will
allow penetration into the male acne market, something not achieved with
currently available hormonal treatments. Furthermore, due to its topical
formulation, systemic side effects are likely to be reduced, if not altogether ameliorated. When compared with
isotretinoin, the current standard for patients with severe acne, ASC-J9 has a
better safety profile and is not teratogenic, which poses a major barrier for
isotretinoin. ASC-J9 is expected to become a major product for the treatment of
patients with severe acne and is forecast to experience rapid uptake.
A
competitive assessment of AndroScience's ASC-J9 and Photocure's Visonac is
provided in the Figure below.
Key Questions Answered
- How will the US and 5EU acne markets evolve over the forecast period from 2012 to 2018 in terms of sales and patient numbers?
- How will the launch of late-stage pipeline therapies such as ASC-J9 and Visonac shape the future treatment landscape?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare to one another and against existing treatment options?
- Why has there been a void of R&D interest from Big Pharma in this highly populated dermatology indication?
- What are the remaining unmet needs and opportunities for drug developers within the acne space?
Spanning over 177 pages, “OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis
and Forecasts to 2018” report covering the Disease
Overview, Epidemiology, Current Treatment Options, Unmet Needs Assessment and
Opportunity Analysis, R&D Strategies, Pipeline Assessment, Pipeline
Valuation Analysis, Appendix.
See
Table of contents & Purchase this publication at: - http://mrr.cm/ZPU
No comments:
Post a Comment
Note: only a member of this blog may post a comment.